- Home
- BIIB vs STLD Comparison
BIIB vs STLD Comparison
Compare BIIB & STLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- STLD
- Stock Information
- Founded
- BIIB 1978
- STLD 1993
- Country
- BIIB United States
- STLD United States
- Employees
- BIIB N/A
- STLD N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- STLD Steel/Iron Ore
- Sector
- BIIB Health Care
- STLD Industrials
- Exchange
- BIIB Nasdaq
- STLD Nasdaq
- Market Cap
- BIIB 25.1B
- STLD 22.3B
- IPO Year
- BIIB 1991
- STLD 1996
- Fundamental
- Price
- BIIB $149.02
- STLD $117.06
- Analyst Decision
- BIIB Buy
- STLD Buy
- Analyst Count
- BIIB 26
- STLD 12
- Target Price
- BIIB $248.00
- STLD $140.67
- AVG Volume (30 Days)
- BIIB 1.6M
- STLD 1.5M
- Earning Date
- BIIB 02-11-2025
- STLD 01-22-2025
- Dividend Yield
- BIIB N/A
- STLD 1.57%
- EPS Growth
- BIIB 10.05
- STLD N/A
- EPS
- BIIB 11.06
- STLD 11.07
- Revenue
- BIIB $9,607,500,000.00
- STLD $17,901,675,000.00
- Revenue This Year
- BIIB N/A
- STLD N/A
- Revenue Next Year
- BIIB N/A
- STLD $2.27
- P/E Ratio
- BIIB $13.47
- STLD $10.57
- Revenue Growth
- BIIB N/A
- STLD N/A
- 52 Week Low
- BIIB $145.07
- STLD $104.60
- 52 Week High
- BIIB $268.30
- STLD $155.56
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- STLD 26.77
- Support Level
- BIIB $145.07
- STLD $114.03
- Resistance Level
- BIIB $149.92
- STLD $139.45
- Average True Range (ATR)
- BIIB 3.81
- STLD 3.30
- MACD
- BIIB 0.05
- STLD -1.94
- Stochastic Oscillator
- BIIB 22.51
- STLD 11.16
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About STLD Steel Dynamics Inc.
Steel Dynamics Inc operates scrap-based steel minimills with roughly 16 million tons of annual steel production capacity. The company's segment includes steel operations, metals recycling operations, steel fabrication operations, Aluminum Operations Segment, and others. It generates maximum revenue from the steel operations segment.